NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Forecast, Price & News $93.36 +5.10 (+5.78%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$88.65▼$93.4550-Day Range$86.94▼$100.3052-Week Range$70.73▼$117.77Volume1.73 million shsAverage Volume1.35 million shsMarket Capitalization$17.52 billionP/E Ratio245.68Dividend YieldN/APrice Target$118.65 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability BioMarin Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.53 Rating ScoreUpside/Downside27.1% Upside$118.65 Price TargetShort InterestBearish3.73% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.77Based on 5 Articles This WeekInsider TradingSelling Shares$7.74 M Sold Last QuarterProj. Earnings Growth143.40%From $1.06 to $2.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.70 out of 5 starsMedical Sector60th out of 983 stocksPharmaceutical Preparations Industry24th out of 486 stocks 4.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.53, and is based on 11 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $118.65, BioMarin Pharmaceutical has a forecasted upside of 27.1% from its current price of $93.36.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.73% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 4.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 2.6 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioMarin Pharmaceutical this week, compared to 5 articles on an average week.Search Interest17 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,735,465.00 in company stock.Percentage Held by InsidersOnly 1.84% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions96.26% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 143.40% in the coming year, from $1.06 to $2.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 245.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 128.16.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 245.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 102.64.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioMarin Pharmaceutical (NASDAQ:BMRN) StockBioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.Read More Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Stock News HeadlinesMay 28, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $119.11 Consensus Price Target from AnalystsMay 26, 2023 | finance.yahoo.comWhy Is BioMarin (BMRN) Down 4% Since Last Earnings Report?June 2, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 23, 2023 | finance.yahoo.comHere’s Why You Should Invest in BioMarin Pharmaceutical (BMRN)May 18, 2023 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Receives New Coverage from Analysts at StockNews.comMay 14, 2023 | americanbankingnews.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $2,845,500.00 in StockMay 5, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $119.11 Consensus Price Target from BrokeragesMay 4, 2023 | finance.yahoo.comBioMarin to Participate in Bank of America 2023 Health Care ConferenceJune 2, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 3, 2023 | finance.yahoo.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2023 Earnings Call TranscriptMay 2, 2023 | msn.comDeath Cross Looms Over Biomarin Pharmaceutical InvestorsMay 2, 2023 | americanbankingnews.comWilliam Blair Weighs in on BioMarin Pharmaceutical Inc.'s Q1 2024 Earnings (NASDAQ:BMRN)May 2, 2023 | americanbankingnews.comFY2023 EPS Estimates for BioMarin Pharmaceutical Inc. Decreased by Analyst (NASDAQ:BMRN)May 1, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)April 30, 2023 | americanbankingnews.comRobert W. Baird Raises BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $127.00April 30, 2023 | americanbankingnews.comGuggenheim Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $120.00April 29, 2023 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded to Buy by StockNews.comApril 28, 2023 | msn.comCitigroup Maintains Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) Neutral RecommendationApril 28, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. to Post Q3 2023 Earnings of $0.29 Per Share, Jefferies Financial Group Forecasts (NASDAQ:BMRN)April 28, 2023 | msn.comRBC Capital Reiterates Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) Sector Perform RecommendationApril 28, 2023 | msn.comPiper Sandler Maintains Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) Overweight RecommendationApril 27, 2023 | markets.businessinsider.comWhat 17 Analyst Ratings Have To Say About Biomarin PharmaceuticalApril 27, 2023 | finance.yahoo.comBioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives SalesApril 27, 2023 | msn.comCredit Suisse Maintains Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) Outperform RecommendationApril 27, 2023 | msn.comWedbush Maintains Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) Neutral RecommendationApril 27, 2023 | finance.yahoo.comBioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to SayApril 26, 2023 | markets.businessinsider.comBiomarin Pharmaceutical Inc. Q1 Profit Decreases, but beats estimatesSee More Headlines BMRN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Company Calendar Last Earnings10/26/2021Today6/02/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,082Year Founded1997Price Target and Rating Average Stock Price Forecast$118.65 High Stock Price Forecast$200.00 Low Stock Price Forecast$74.00 Forecasted Upside/Downside+27.1%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$0.38 Trailing P/E Ratio245.68 Forward P/E Ratio88.08 P/E GrowthN/ANet Income$141.56 million Net Margins3.30% Pretax Margin3.32% Return on Equity4.02% Return on Assets2.92% Debt Debt-to-Equity Ratio0.23 Current Ratio4.75 Quick Ratio3.21 Sales & Book Value Annual Sales$2.10 billion Price / Sales8.36 Cash Flow$1.58 per share Price / Cash Flow59.01 Book Value$24.82 per share Price / Book3.76Miscellaneous Outstanding Shares187,700,000Free Float184,247,000Market Cap$17.52 billion OptionableOptionable Beta0.38 Social Links Key ExecutivesJean-Jacques BienaiméChairman & Chief Executive OfficerBrian R. MuellerChief Financial Officer & Executive VP-FinanceEduardo E. von PervieuxChief Information OfficerHenry J. FuchsPresident-Worldwide Research & DevelopmentKevin EgganGroup VP, Head-Research & Early DevelopmentKey CompetitorsUnited TherapeuticsNASDAQ:UTHRAlnylam PharmaceuticalsNASDAQ:ALNYIonis PharmaceuticalsNASDAQ:IONSMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 5,258 shares on 5/26/2023Ownership: 0.007%Toroso Investments LLCBought 388 shares on 5/23/2023Ownership: 0.003%Ameriprise Financial Inc.Bought 274,718 shares on 5/22/2023Ownership: 2.631%International Biotechnology Trust PLCBought 15,000 shares on 5/18/2023Ownership: 0.031%B. Riley Wealth Advisors Inc.Sold 281 shares on 5/17/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions BMRN Stock - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price forecast for 2023? 19 analysts have issued 12 month price objectives for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $74.00 to $200.00. On average, they anticipate the company's share price to reach $118.65 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2023? BioMarin Pharmaceutical's stock was trading at $103.49 at the start of the year. Since then, BMRN shares have decreased by 9.8% and is now trading at $93.36. View the best growth stocks for 2023 here. When is BioMarin Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our BMRN earnings forecast. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to analysts' expectations of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 4.02% and a net margin of 3.30%. BioMarin Pharmaceutical's revenue for the quarter was down 14.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 earnings per share. What ETFs hold BioMarin Pharmaceutical's stock? ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), VanEck Biotech ETF (BBH), Goldman Sachs Future Health Care Equity ETF (GDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), VictoryShares Nasdaq Next 50 ETF (QQQN), Touchstone US Large Cap Focused ETF (LCF) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $1.80-$2.05 for the period, compared to the consensus EPS estimate of $0.95. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.46 billion. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dodge & Cox (7.63%), Ameriprise Financial Inc. (2.63%), Avoro Capital Advisors LLC (2.10%), Baker BROS. Advisors LP (2.03%), Geode Capital Management LLC (1.42%) and Pictet Asset Management SA (1.09%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $93.36. How much money does BioMarin Pharmaceutical make? BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $17.52 billion and generates $2.10 billion in revenue each year. The biotechnology company earns $141.56 million in net income (profit) each year or $0.38 on an earnings per share basis. How many employees does BioMarin Pharmaceutical have? The company employs 3,082 workers across the globe. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889. This page (NASDAQ:BMRN) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.